tetano
Editor, Senior Moderator
Front Immunol
. 2021 Nov 3;12:772239.
doi: 10.3389/fimmu.2021.772239. eCollection 2021.
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection
Gabriel Siracusano[SUP] 1 [/SUP], Chiara Brombin[SUP] 2 [/SUP], Claudia Pastori[SUP] 1 [/SUP], Federica Cugnata[SUP] 2 [/SUP], Maddalena Noviello[SUP] 3 [/SUP], Elena Tassi[SUP] 3 [/SUP], Denise Princi[SUP] 1 [/SUP], Diego Cantoni[SUP] 4 [/SUP], Mauro S Malnati[SUP] 5 [/SUP], Norma Maugeri[SUP] 6 [/SUP], Carla Bozzi[SUP] 7 [/SUP], Gianni Saretto[SUP] 7 [/SUP], Nicola Clementi[SUP] 8 [/SUP], Nicasio Mancini[SUP] 8 [/SUP], Caterina Uberti-Foppa[SUP] 9 [/SUP], Nigel Temperton[SUP] 4 [/SUP], Chiara Bonini[SUP] 10 [/SUP], Clelia Di Serio[SUP] 2 11 [/SUP], Lucia Lopalco[SUP] 1 [/SUP]
Affiliations
Abstract
This contribution explores in a new statistical perspective the antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus disease 2019 (COVID-19) patients exhibiting a broad range of clinical manifestations. This cohort accurately reflects the characteristics of the first wave of the SARS-CoV-2 pandemic in Italy. We determined the IgM, IgA, and IgG levels towards SARS-CoV-2 S1, S2, and NP antigens, evaluating their neutralizing activity and relationship with clinical signatures. Moreover, we longitudinally followed 72 patients up to 9 months postsymptoms onset to study the persistence of the levels of antibodies. Our results showed that the majority of COVID-19 patients developed an early virus-specific antibody response. The magnitude and the neutralizing properties of the response were heterogeneous regardless of the severity of the disease. Antibody levels dropped over time, even though spike reactive IgG and IgA were still detectable up to 9 months. Early baseline antibody levels were key drivers of the subsequent antibody production and the long-lasting protection against SARS-CoV-2. Importantly, we identified anti-S1 IgA as a good surrogate marker to predict the clinical course of COVID-19. Characterizing the antibody response after SARS-CoV-2 infection is relevant for the early clinical management of patients as soon as they are diagnosed and for implementing the current vaccination strategies.
Keywords: COVID-19; SARS-CoV-2; VOC; clinical outcome; neutralizing antibodies.
. 2021 Nov 3;12:772239.
doi: 10.3389/fimmu.2021.772239. eCollection 2021.
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection
Gabriel Siracusano[SUP] 1 [/SUP], Chiara Brombin[SUP] 2 [/SUP], Claudia Pastori[SUP] 1 [/SUP], Federica Cugnata[SUP] 2 [/SUP], Maddalena Noviello[SUP] 3 [/SUP], Elena Tassi[SUP] 3 [/SUP], Denise Princi[SUP] 1 [/SUP], Diego Cantoni[SUP] 4 [/SUP], Mauro S Malnati[SUP] 5 [/SUP], Norma Maugeri[SUP] 6 [/SUP], Carla Bozzi[SUP] 7 [/SUP], Gianni Saretto[SUP] 7 [/SUP], Nicola Clementi[SUP] 8 [/SUP], Nicasio Mancini[SUP] 8 [/SUP], Caterina Uberti-Foppa[SUP] 9 [/SUP], Nigel Temperton[SUP] 4 [/SUP], Chiara Bonini[SUP] 10 [/SUP], Clelia Di Serio[SUP] 2 11 [/SUP], Lucia Lopalco[SUP] 1 [/SUP]
Affiliations
- PMID: 34804064
- PMCID: PMC8595940
- DOI: 10.3389/fimmu.2021.772239
Abstract
This contribution explores in a new statistical perspective the antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 141 coronavirus disease 2019 (COVID-19) patients exhibiting a broad range of clinical manifestations. This cohort accurately reflects the characteristics of the first wave of the SARS-CoV-2 pandemic in Italy. We determined the IgM, IgA, and IgG levels towards SARS-CoV-2 S1, S2, and NP antigens, evaluating their neutralizing activity and relationship with clinical signatures. Moreover, we longitudinally followed 72 patients up to 9 months postsymptoms onset to study the persistence of the levels of antibodies. Our results showed that the majority of COVID-19 patients developed an early virus-specific antibody response. The magnitude and the neutralizing properties of the response were heterogeneous regardless of the severity of the disease. Antibody levels dropped over time, even though spike reactive IgG and IgA were still detectable up to 9 months. Early baseline antibody levels were key drivers of the subsequent antibody production and the long-lasting protection against SARS-CoV-2. Importantly, we identified anti-S1 IgA as a good surrogate marker to predict the clinical course of COVID-19. Characterizing the antibody response after SARS-CoV-2 infection is relevant for the early clinical management of patients as soon as they are diagnosed and for implementing the current vaccination strategies.
Keywords: COVID-19; SARS-CoV-2; VOC; clinical outcome; neutralizing antibodies.